Update in the management of chronic hepatitis B

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To review the recent developments in the management of chronic hepatitis B (CHB) based on the articles published between January 2012 and January 2013. RECENT FINDINGS: International guidelines have been updated to include recent discoveries in the natural history of CHB, how to determine who should be treated, recommendations of management of special populations, and support of highly potent medications with high genetic barrier to resistance as the first-line therapy. Sustained response rates to interferon may be influenced by the IL28B genotype and can be predicted by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA. Long-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resistance, leading to decreased rates of hepatocellular carcinoma and death. SUMMARY: Current therapies suppress, but rarely eradicate hepatitis B. Drug resistance remains a barrier to success in the long-term treatment of CHB, especially in resource-poor areas and in previously treated patients. Quantitative hepatitis B surface antigen in addition to other clinical data may provide personalized treatment decisions based on risk and response. There remains a need for novel therapies targeting HBV replication and immune system for CHB cure.

Original languageEnglish (US)
Pages (from-to)250-256
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume29
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Chronic Hepatitis B
Tenofovir
Hepatitis B Surface Antigens
Hepatitis B virus
Therapeutics
Multiple Drug Resistance
Virus Replication
Hepatitis B
Drug Resistance
Interferons
Hepatocellular Carcinoma
Immune System
Genotype
Guidelines
DNA
Population

Keywords

  • antiviral therapy
  • chronic hepatitis B
  • chronic liver disease
  • nucleos(t)ide analogs

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Update in the management of chronic hepatitis B. / Tujios, Shannan R.; Lee, William M.

In: Current Opinion in Gastroenterology, Vol. 29, No. 3, 05.2013, p. 250-256.

Research output: Contribution to journalArticle

@article{1c7a2a33b75f431999cd5976800a5140,
title = "Update in the management of chronic hepatitis B",
abstract = "PURPOSE OF REVIEW: To review the recent developments in the management of chronic hepatitis B (CHB) based on the articles published between January 2012 and January 2013. RECENT FINDINGS: International guidelines have been updated to include recent discoveries in the natural history of CHB, how to determine who should be treated, recommendations of management of special populations, and support of highly potent medications with high genetic barrier to resistance as the first-line therapy. Sustained response rates to interferon may be influenced by the IL28B genotype and can be predicted by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA. Long-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resistance, leading to decreased rates of hepatocellular carcinoma and death. SUMMARY: Current therapies suppress, but rarely eradicate hepatitis B. Drug resistance remains a barrier to success in the long-term treatment of CHB, especially in resource-poor areas and in previously treated patients. Quantitative hepatitis B surface antigen in addition to other clinical data may provide personalized treatment decisions based on risk and response. There remains a need for novel therapies targeting HBV replication and immune system for CHB cure.",
keywords = "antiviral therapy, chronic hepatitis B, chronic liver disease, nucleos(t)ide analogs",
author = "Tujios, {Shannan R.} and Lee, {William M.}",
year = "2013",
month = "5",
doi = "10.1097/MOG.0b013e32835ff1e9",
language = "English (US)",
volume = "29",
pages = "250--256",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update in the management of chronic hepatitis B

AU - Tujios, Shannan R.

AU - Lee, William M.

PY - 2013/5

Y1 - 2013/5

N2 - PURPOSE OF REVIEW: To review the recent developments in the management of chronic hepatitis B (CHB) based on the articles published between January 2012 and January 2013. RECENT FINDINGS: International guidelines have been updated to include recent discoveries in the natural history of CHB, how to determine who should be treated, recommendations of management of special populations, and support of highly potent medications with high genetic barrier to resistance as the first-line therapy. Sustained response rates to interferon may be influenced by the IL28B genotype and can be predicted by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA. Long-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resistance, leading to decreased rates of hepatocellular carcinoma and death. SUMMARY: Current therapies suppress, but rarely eradicate hepatitis B. Drug resistance remains a barrier to success in the long-term treatment of CHB, especially in resource-poor areas and in previously treated patients. Quantitative hepatitis B surface antigen in addition to other clinical data may provide personalized treatment decisions based on risk and response. There remains a need for novel therapies targeting HBV replication and immune system for CHB cure.

AB - PURPOSE OF REVIEW: To review the recent developments in the management of chronic hepatitis B (CHB) based on the articles published between January 2012 and January 2013. RECENT FINDINGS: International guidelines have been updated to include recent discoveries in the natural history of CHB, how to determine who should be treated, recommendations of management of special populations, and support of highly potent medications with high genetic barrier to resistance as the first-line therapy. Sustained response rates to interferon may be influenced by the IL28B genotype and can be predicted by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA. Long-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resistance, leading to decreased rates of hepatocellular carcinoma and death. SUMMARY: Current therapies suppress, but rarely eradicate hepatitis B. Drug resistance remains a barrier to success in the long-term treatment of CHB, especially in resource-poor areas and in previously treated patients. Quantitative hepatitis B surface antigen in addition to other clinical data may provide personalized treatment decisions based on risk and response. There remains a need for novel therapies targeting HBV replication and immune system for CHB cure.

KW - antiviral therapy

KW - chronic hepatitis B

KW - chronic liver disease

KW - nucleos(t)ide analogs

UR - http://www.scopus.com/inward/record.url?scp=84876285519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876285519&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32835ff1e9

DO - 10.1097/MOG.0b013e32835ff1e9

M3 - Article

VL - 29

SP - 250

EP - 256

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -